The Directors are buying to pump the share price IMHO. They are small investments in the scheme of things. Watch out as they go to market cap in hand for more funding. For those who want to know where the 'insufficient clinical benefit' call came from, take a look at this article, especially the section on p-values/statistical significance: https://www.newyorker.com/magazine/2019/09/09/what-statistics-can-and-cant-tell-us-about-ourselves
More reading here: Fooled by Randomness: The Hidden Role of Chance in Life and in the Markets and The Signal and the Noise: Why so Many Predictions Fail - But Some Don't.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.00 |
Change
0.030(3.09%) |
Mkt cap ! $14.22M | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.00 | 96.0¢ | $39.65K | 40.44K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3000 | 96.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.01 | 391 | 2 |
View Market Depth
| Last trade - 16.10pm 24/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |